Using 18F- FDG,18F-DOPA and 68Ga-DOTATATE PET/CT in Detection and Evaluation of Response in Patients With NET Undergoing PRRT
NCT04622631 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80
Last updated 2020-11-10
Summary
the investigators will follow up after patients with neuroendocrine tumors who undergo PRRT treatment and evaluate the response for treatment using PET/CT with different tracers
Conditions
Sponsors & Collaborators
-
Sheba Medical Center
collaborator OTHER_GOV -
Dr. Nayruz Knaana
lead OTHER_GOV
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-11-30
- Primary Completion
- 2022-01-31
- Completion
- 2023-01-31
Countries
- Israel
Study Locations
More Related Trials
-
Applying PET/MR in Neuroendocrine Tumors - Imaging Dynamic Processes in Both Modalities
NCT04152928 ·Status: UNKNOWN ·Phase: NA
-
68Ga-HA-DOTATATE PET/CT in Adults With Neuroendocrine Tumors
NCT05673031 ·Status: RECRUITING
-
Nonfunctional Pancreatic NET and PET Imaging
NCT02621541 ·Status: UNKNOWN ·Phase: PHASE4
-
A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Healthy Volunteers in Japan
NCT06240741 ·Status: COMPLETED ·Phase: PHASE3
-
68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)
NCT02174679 ·Status: NO_LONGER_AVAILABLE
-
Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
NCT01967537 ·Status: COMPLETED ·Phase: PHASE2
-
Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan
NCT03136328 ·Status: COMPLETED ·Phase: PHASE3
-
68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors
NCT03001349 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours
NCT01673906 ·Status: COMPLETED ·Phase: PHASE2
-
Dual SSTR2 and Integrin αvβ3 Targeting PET/CT Imaging
NCT02817945 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
PET/CT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105
NCT03278275 ·Status: COMPLETED ·Phase: PHASE2
-
Ga68-DOTA-NOC-PET Imaging of Neuroendocrine Tumors
NCT00569738 ·Status: UNKNOWN
-
PET-CT Imaging of Neuro-endocrine Tumors and Preliminary Clinical Evaluation
NCT02134639 ·Status: COMPLETED
-
[68 Ga]-DOTANOC PET/CT in GEP-NETs
NCT02608203 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
The Role of FDG PET in Radiation Treatment Planning for Head and Neck Cancers
NCT00230269 ·Status: COMPLETED
-
Dual-Tracer Theranostic PET
NCT05680675 ·Status: COMPLETED ·Phase: NA
-
68Ga-DOTATATE PET Scan in Neuroendocrine Cancer
NCT01396382 ·Status: COMPLETED ·Phase: PHASE2
-
The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Pancreatic Cancer.
NCT06601010 ·Status: RECRUITING
-
TEP With 68-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors
NCT01747096 ·Status: COMPLETED ·Phase: NA
-
An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer
NCT07132645 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Validation of 99mTc- EDDA - HYNIC -TOC Kits for Diagnosis of Neuroendocrine Tumors
NCT02691078 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of the Diagnostic and Prognostic Role of PET (PET/CT and PET/MRI) in Neuroendocrin Tumors.
NCT06159920 ·Status: RECRUITING
-
68Ga-DOTATATE PET for Management of Neuroendocrine Tumors
NCT03873870 ·Status: COMPLETED ·Phase: NA
-
68Ga-DOTATATE PET/CT in Neuroendocrine Tumor
NCT04041882 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
PET/CT Imaging of Angiogenesis in Patients With Neuroendocrine Tumors Using 68Ga-NODAGA-E[c(RGDyK)]2
NCT03271281 ·Status: COMPLETED ·Phase: PHASE2